Economics of Increasing Sorghum Productivity in Sub-Saharan Africa: The Mali Case.

Sorghum retains a crucial role in Sub-Saharan Africa for food and in the future feed. Unfortunately, the movement of sorghum technology onto farmers' fields in Sub-Saharan Africa has been slow in spite of substantial research since the great African drought of 1968-1973. What is necessary to get African sorghum yields and profitability up?After reviewing the situation of sorghum in the world, the USA, and Sub-Saharan Africa from 2007 to 2017 the results and the lessons of a twelve-year program in the Sahel of West Africa to introduce new sorghum technology and marketing strategies are the focus of the rest of the paper. In Mali, the program identified new technologies that were extended into a large number of farmers' associations. The Mali program then collaborated with two other agencies to scale up this pilot program. The pilot project demonstrated that yields with moderate fertilization, new varieties, and improved agronomic practices could be increased 50 to 100% and prices increased 30 to 50%. The 2012 military coup and then invasion of Al Queda from the north shut down both the pilot and the scaling up activities as the US government banned collaboration with Malian government agencies after the coup. The pilots were continued in Niger and Burkina Faso through 2014 and then with a Gates Foundation grant from 2014 to 2016. The pilot program in Mali responded to two of the three Second Generation problems identified. But more significantly the pilot project identified the lack of funds for responding to Second Generation problems as a major constraint for implementing a technology-marketing program in a low-income country.

Mitral valve repair and replacement in northern New England.

BACKGROUND: The etiology of mitral valvular disease has changed in the last 20 years, and new techniques for the diagnosis and repair of mitral valves have been advanced. A retrospective regional study was conducted to identify changes in patient and disease characteristics and in population-based rates for mitral valve repair and replacement in northern New England. METHODS: Data from 1648 patients were collected from 5 clinical centers in Maine, New Hampshire, and Vermont between January 1, 1990, and December 31, 1999. U.S. Census data were used to calculate population-based rates. RESULTS: Total mitral valve procedures increased 2.4 times, from 8.7 to 20.6 cases/100,000/year (p(trend) = 0.004). Primary procedures increased from 6.7 to 16.9 cases/100,000/year (p(trend) = 0.014). Primary mitral valve repair procedures increased 3.7 times, from 2.4 to 8.9 cases/100,000/year (p(trend) = 0.012), whereas mitral valve replacement increased only 1.9 times, from 4.3 to 8.0 cases/100,000/year (p(trend) = 0.016). Repeat mitral valve operations did not change significantly (p(trend) = 0.810). During this period, there was a significant increase of the percentage of octogenarians (p(trend) = 0.016) and of patients with ejection fractions <40% (p(trend) = 0.012). There was a decrease in the percentage of patients with mitral stenosis (p(trend) = 0.024). CONCLUSION: In an era of a change in the etiology of mitral valvular disease and new techniques for diagnosis and repair of mitral valvular disease, regional data demonstrate substantial increased rates of mitral repair and replacement and expanded indications of older age and poorer left ventricular function.

Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in Northern New England.

BACKGROUND: Predicting risk for aortic and mitral valve surgery is important both for informed consent of patients and objective review of surgical outcomes. Development of reliable prediction rules requires large data sets with appropriate risk factors that are available before surgery. METHODS: Data from eight Northern New England Medical Centers in the period January 1991 through December 2001 were analyzed on 8943 heart valve surgery patients aged 30 years and older. There were 5793 cases of aortic valve replacement and 3150 cases of mitral valve surgery (repair or replacement). Logistic regression was used to examine the relationship between risk factors and in-hospital mortality. RESULTS: In the multivariable analysis, 11 variables in the aortic model (older age, lower body surface area, prior cardiac operation, elevated creatinine, prior stroke, New York Heart Association [NYHA] class IV, congestive heart failure [CHF], atrial fibrillation, acuity, year of surgery, and concomitant coronary artery bypass grafting) and 10 variables in the mitral model (female sex, older age, diabetes, coronary artery disease, prior cerebrovascular accident, elevated creatinine, NYHA class IV, CHF, acuity, and valve replacement) remained independent predictors of the outcome. The mathematical models were highly significant predictors of the outcome, in-hospital mortality, and the results are in general agreement with those of others. The area under the receiver operating characteristic curve for the aortic model was 0.75 (95% confidence interval [CI], 0.72 to 0.77), and for the mitral model, 0.79 (95% CI, 0.76 to 0.81). The goodness-of-fit statistic for the aortic model was chi(2) [8 df] = 11.88, p = 0.157, and for the mitral model it was chi(2) [8 df] = 5.45, p = 0.708. CONCLUSIONS: We present results and methods for use in day-to-day practice to calculate patient-specific in-hospital mortality after aortic and mitral valve surgery, by the logistic equation for each model or a simple scoring system with a look-up table for mortality rate.

The Carpentier-Edwards stented supra-annular pericardial aortic valve prosthesis: clinical durability and hemodynamic performance.

There are encouraging reports of satisfactory long-term experiences with second-generation stent-mounted glutaraldehyde-fixed pericardial aortic valve prostheses. Durability has improved, but the issue has not been completely resolved. There is disagreement whether the small sizes of these prostheses are associated with inferior outcomes. Large-scale, long-term multivariable analyses of actual clinical results are needed to complement actuarial calculations of important end points from multiple small series to improve the ability to match individual patients with prostheses that suit their needs and preferences.

Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery.

OBJECTIVE: To measure the effects of glucocorticoids on the systemic inflammatory response and clinical recovery after cardiac surgery. DESIGN: Randomized, prospective, double-blind, placebo-controlled clinical trial with concurrent comparison groups. SETTING: University medical center. PARTICIPANTS: Patients scheduled for elective coronary artery bypass graft surgery using normothermic cardiopulmonary bypass (CPB) and a standardized anesthetic. INTERVENTIONS: Participants randomly received either methylprednisolone, 15 mg/kg intravenously 1 hour before surgery and 0.3 mg/kg intravenously every 6 hours x 4 doses, or placebo. Comparison groups included cardiac surgical patients who received etomidate to lower endogenous cortisol during surgery and healthy volunteers who received methylprednisolone only. MEASUREMENTS AND MAIN RESULTS: Patients who received methylprednisolone had a significant reduction in circulating interleukin (IL)-6 at 60 minutes after CPB (p < 0.05) and on the morning of the 1st (p < 0.01) and 3rd (p < 0.05) postoperative days and a significant increase in circulating IL-10 at 60 minutes after CPB (p < 0.01) compared with the placebo group. Etomidate, given to lower cortisol during surgery, was associated with significantly decreased IL-6 and IL-10 responses to surgery compared with the placebo group, whereas methylprednisolone alone, given to healthy nonsurgical volunteers, had no effect on these cytokines. After adjusting for age, there were no significant differences in postoperative length of hospital stay between the methylprednisolone-treated (4.6 days) and placebo (6.1 days) groups or in the duration of mechanical ventilation (9.9 hours and 15.6 hours). No patient treated with methylprednisolone had nausea and vomiting on the 1st postoperative day compared with 33% of placebo-treated patients (p = 0.02). Glucose was significantly higher after methylprednisolone treatment at 1 hour after CPB (276 mg/dL v 210 mg/dL; p = 0.001) and at 2 hours (289 mg/dL v 213 mg/dL; p = 0.009) and 8 hours (247 mg/dL v 196 mg/dL; p = 0.02) after surgery. There were no differences in pain scores and no significant intergroup differences in lung peak expiratory flow rate or alveolar-arterial oxygen gradients after surgery. CONCLUSION: This study shows significant effects of glucocorticoids on the production of IL-6 and IL-10 in response to cardiac surgery but only minor effects on clinical recovery.